News

DiaCarta Advances Blood Test for Colorectal Cancer Screening

DiaCarta Advances Blood Test for Colorectal Cancer Screening

DiaCarta's Positive Clinical Trial Results Unveiled

DiaCarta Inc., a pioneering molecular diagnostic firm, has recently shared encouraging clinical trial findings regarding its innovative blood-based test designed for triaging patients who test positive for the fecal immunochemical test (FIT) in colorectal cancer (CRC) screening. This groundbreaking study data, released through the Journal of Molecular Pathology, highlights how the QuantiDNA™ test can effectively minimize the necessity for colonoscopy procedures by 33%, demonstrating that it is on par with standard methods for identifying significant colorectal lesions.

Details of the Clinical Trial Study

The clinical trial, focused on the Triage of FIT Positive Patients enrolled in CRC screening initiatives, took place between 2019 and 2022. A total of 711 participants of various backgrounds, aged between 50 and 74 years, took part in a comprehensive study organized by a public healthcare entity. Individuals who exhibited a FIT+ result and agreed to study participation were subjected to both the blood test and a follow-up colonoscopy. This approach ensured a thorough comparison between traditional practices and the new blood-based technique. The trial received ethical approval in late 2018 and statistical analyses were rigorously conducted to validate the outcomes.

The Clinical Significance

Dr. Mauro Scimia, Medical Director and Senior Business Director of DiaCarta, emphasized the potential of this study in reforming CR screening protocols. He mentioned that in Europe, a majority of patients who are initially diagnosed as FIT positive ultimately do not have significant findings upon colonoscopy, which leads to unnecessary procedures and anxiety for patients. By implementing the QuantiDNA™ test, healthcare providers can improve patient experiences while managing resources more effectively.

The Company and Its Vision

Dr. Adam (Aiguo) Zhang, DiaCarta’s President and CEO, also expressed his satisfaction with the trial results. He noted that the strong performance of the blood-based test not only meets the company’s mission of enhancing cancer testing via liquid biopsy but also marks a vital step toward integrating the test into everyday clinical practice.

About DiaCarta

Founded with a commitment to transformation in patient care, DiaCarta is at the forefront of molecular diagnostics. Their revolutionary XNA technology grants high sensitivity in detecting biomarkers crucial for early cancer detection. Particularly, their early detection test for colorectal cancer reflects their efforts towards successful healthcare innovations.

Additionally, DiaCarta has introduced the isobDNA™ technology, further enhancing detection levels while eradicating the need for complex RNA/DNA extraction processes. The RadTox™ pan-cancer blood test is another product that personalizes cancer treatments, providing real-time insights into tumor responses and treatment efficacy.

Company's Operations and Commitment to Quality

Based in Pleasanton, California, DiaCarta operates an ISO-certified and GMP-compliant facility, offering CLIA-certified laboratory services. Their tests are not only effective but also accessible, as they are covered by most medical insurances.

Contacting DiaCarta

All inquiries regarding DiaCarta's services or studies can be directed through the following:

Phone Number: 1-800-246-8878

Email: [email protected]

Frequently Asked Questions

What is the purpose of DiaCarta's blood test?

The blood test is designed to triage patients who test positive for colorectal cancer screening, reducing unnecessary colonoscopies.

What were the findings of the clinical trial?

The trial showed a 33% reduction in the need for colonoscopy while maintaining efficacy in detecting significant lesions.

Who conducted the clinical trial?

The trial involved collaboration with a public healthcare organization and was approved by the appropriate ethical committees.

What technologies does DiaCarta utilize?

DiaCarta employs innovative technologies like XNA and isobDNA™ for developing sensitive diagnostic tests for early cancer detection.

How can I contact DiaCarta for more information?

You can reach DiaCarta by phone at 1-800-246-8878 or through their official email for inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 62

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 59

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 95

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 38

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 43

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 83

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 56

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 36

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 70

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading

Top 5 Most Recently Viewed Articles

Flat Glass Market Growth and Future Trends Analysis

Updated Category News Views 256

Overview of the Flat Glass Market The flat glass market is on a remarkable trajectory, currently valued at USD 179.80 billion and poised to soar to USD 280.64 billion in the next few years, reflecting a compound annual growth rate (CAGR) of 8.0%. This growth is predominantly fueled by the booming construction and automotive sectors, coupled with a rising demand for...

Continue Reading
The Everglades Foundation Achieves Historic Fundraising Success

Updated Category News Views 435

Celebrating a Milestone for the Everglades Foundation The Everglades Foundation has achieved a monumental success, surpassing its fundraising target during its inaugural endowment campaign. With a remarkable outpouring of support, the Foundation raised $76 million in gifts and pledges from a dedicated group of 80 donors. This significant achievement ensures the long-term...

Continue Reading
Exploring Government's Generative AI Challenges and Solutions

Updated Category News Views 148

Understanding Government's Generative AI Landscape Government agencies are expressing considerable optimism about the potential of Generative AI (GenAI) technology, even as they face challenges in its implementation. Recent insights highlight that while budgeting for these innovations is high, the actual deployment of GenAI remains behind other industries. Survey findings...

Continue Reading
Key Information for DXC Technology Investors Ahead of Deadline

Updated Category News Views 71

Your Rights as a DXC Technology Investor If you're an investor in DXC Technology Company (NYSE: DXC), it’s important to understand your rights and the ongoing legal issues that could impact you. Bernstein Liebhard LLP, a well-respected law firm, wants to remind all DXC shareholders of a critical deadline that’s approaching. Who Needs to Be Concerned? Do you own shares...

Continue Reading
LM Funding America Inc. Reports Q3 2024 Results and Outlook

Updated Category News Views 115

Business Update and Financial Highlights LM Funding America, Inc. (NASDAQ: LMFA) has recently shared its financial results for the third quarter of 2024. This Tampa-based company focuses on cryptocurrency mining and technological finance solutions, showcasing significant strategic developments in its operations. Bitcoin Holdings and Revenue Performance As of September 30,...

Continue Reading